Health Care · Biotechnology

Tarsus Pharmaceuticals, Inc. TARS

$58.60-0.35 (-0.60%)delayed quote · as of 2026-07-29 14:30 UTC

Open TARS in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$2.6B

Previous close

$58.95

Volume

76K

52-week range

$38.51 – $85.25

Verdictconfidence 69% · moderate

Growth stands out; quality flashes caution.

2 of 5 dimensions score well; quality flashes caution. Value and Momentum not scored — not enough data.

Value—0/2 checks

Growth753/4 checks

Quality402/5 checks

Health603/5 checks

Momentum—0/2 checks

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

35.3

EV/EBITDA TTM

—

PEG

—

FCF yield TTM

-1.2%

Growth

Revenue 3y

+159.5%/yr

Revenue YoY

+146.7%

Expected EPS

—

Quality

Piotroski F

4 / 9

ROIC

-930.8%

Gross margin

—

Health

Altman Z

7.16

Current ratio

3.85

Debt/equity

0.21

Momentum

vs 50-day

—

vs 200-day

—

52-wk range

43%

FY 2025: revenue $451.4M · net income -$66.4M · free cash flow -$22.3M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-29 14:30 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading TARS’s filed statements…

Continue with TARS in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.